IBER.U (Ibere Pharmaceuticals) EBIT per Share : $0.00 (TTM As of Sep. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Ibere Pharmaceuticals EBIT per Share?

Ibere Pharmaceuticals's EBIT per Share for the three months ended in Sep. 2022 was $0.00. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2022 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Ibere Pharmaceuticals's EBIT per Share or its related term are showing as below:

IBER.U's 3-Year EBIT Growth Rate is not ranked ^*
in the Diversified Financial Services industry.
Industry Median: 3.55
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Ibere Pharmaceuticals's EBIT for the three months ended in Sep. 2022 was $-0.23 Mil.

Ibere Pharmaceuticals EBIT per Share Historical Data

The historical data trend for Ibere Pharmaceuticals's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ibere Pharmaceuticals EBIT per Share Chart

Ibere Pharmaceuticals Annual Data

Trend

Dec20

Dec21

EBIT per Share

Ibere Pharmaceuticals Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
EBIT per Share	Get a 7-Day Free Trial			-	-	-	-	-

Ibere Pharmaceuticals EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Ibere Pharmaceuticals's EBIT per Share for the fiscal year that ended in Dec. 2021 is calculated as

	EBIT per Share		(A: Dec. 2021 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-1.004	/	0
=	N/A

Ibere Pharmaceuticals's EBIT per Share for the quarter that ended in Sep. 2022 is calculated as

	EBIT per Share		(Q: Sep. 2022 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-0.234	/	0
=	N/A

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00

Ibere Pharmaceuticals (NYSE:IBER.U) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Ibere Pharmaceuticals EBIT per Share Related Terms

Thank you for viewing the detailed overview of Ibere Pharmaceuticals's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Ibere Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Ibere Pharmaceuticals (NYSE:IBER.U) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

2005 Market Street, Suite 2030, Philadelphia, PA, USA, 19103

Website

https://www.iberepharma.com

Ibere Pharmaceuticals is a blank check company.

Executives

Elaine V Jones	director	C/O TARGACEPT, INC., 200 EAST FIRST STREET, SUITE 300, WINSTON-SALEM NC 27101
Osagie O Imasogie	director, 10 percent owner, officer: Chief Executive Officer
Calvin B. Johnson	director	2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103
Zoltan Kerekes	director, 10 percent owner, officer: Chief Operating Officer	2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103
Louis J. Vollmer	director	2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103
Lisa M. Gray	director, 10 percent owner, officer: Chief Financial Officer	2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103
Henrietta Ukwu	director	2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103
Pipv Capital Llc	10 percent owner	2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103

Ibere Pharmaceuticals Headlines

From GuruFocus

Ibere Pharmaceuticals Receives Expected NYSE Notice Regarding Delayed Quarterly Report

By PRNewswire PRNewswire • 05-28-2021

Ibere Pharmaceuticals Announces Closing of $138,000,000 Initial Public Offering

By PRNewswire PRNewswire • 03-03-2021